Hypoxia is a common feature of lung cancers. Nonetheless, no guidelines have been established to integrate hypoxia-associated biomarkers in patient management. Here, we discuss the current knowledge and provide translational novel considerations regarding its clinical detection and targeting to improve the outcome of patients with non-small-cell lung carcinoma of all stages. READ ARTICLE

Cancers DOI: 10.3390/cancers13143421

Authors: Ancel J, Perotin J-M, Dewolf M, Launois C, Mulette P, Nawrocki-Raby B, Dalstein V, Gilles C, Deslée G, Polette M and Dormoy V.

Read More